

**NHS Prescription Services** 

Bridge House 152 Pilgrim Street Newcastle upon Tyne NE1 6SN 0845 850 0001

Email: nhsbsa.prescriptionservices@nhsbsa.nhs.uk

Website: www.nhsbsa.nhs.uk

03 Mar 2025

VERSION 3.0.0

Dear dm+d User,

#### **Update on impact of reuse of identifiers**

We are extending the deadline to seek further feedback from users. We would appreciate feedback preferably no later than **Friday 7**<sup>th</sup> **March**, although suppliers are welcome to email us at <a href="mailto:dmdenquiries@nhsbsa.nhs.uk">dmdenquiries@nhsbsa.nhs.uk</a> with any comments, concerns or queries beyond this date.

The recent work on adding ingredients to Virtual Therapeutic Moieties (VTMs) has been carried out. Where the VTM identifier is an International SNOMED identifier for a "contains only" Medicinal product concept then the assigned ingredient concept must also have an International SNOMED identifier.

This work has identified an issue.

- Currently the dm+d Editorial Policy states that SNOMED identifiers must not be reused or assigned to another concept even where the concept identifier has been subsequently updated in dm+d.
- Appendix XXVI of the dm+d Editorial Policy details five ingredient concepts that have a SNOMED CT UK Extension identifier in dm+d but they have an International identifier in the SNOMED CT UK Drug Extension. These ingredient identifiers cannot be updated to International identifiers
- Because of the above points the VTM concepts that should have these ingredient concepts assigned to them do not currently have ingredients in dm+d.
- Appendix XXVI is in the process of being updated to include another ingredient concept where the international identifier cannot be allocated Perflutren.

- The SNOMED CT UK Drug Extension handles the above through the use of both current and historical, relationship types for example 'replaced by', 'same as' etc. Also inactive and active concepts are identified in SNOMED but dm+d is unable to do this for ingredient concepts.
- Currently in dm+d if these ingredient concepts were required to be assigned to the VTM concepts it would only be possible to create the ingredient concept with a UK Extension identifier in dm+d. This UK Extension identifier would be inactive in the SNOMED CT UK Drug Extension with a SAME\_AS relationship to the International identifier concept
- This therefore introduces misalignment between the same VTM concepts in dm+d and the SNOMED CT UK Drug Extension.

Concern has been raised that as the terminologies evolve, more examples of this misalignment between them will come to light over time. Prior to proceeding with the assignation (or not) of ingredients to these VTMs in dm+d, the dm+d and NHSE Terminology teams sought feedback from system suppliers on the potential impact of reusing these particular codes (note – any reuse would always be noted in outgoing comms to alert system suppliers).

For the example below, suppliers were asked, "what would be the impact upon your system and users **IF** the ingredient Sevelamer (or any of the other examples in the appendix) was assigned the international ID".

Ingredient	dm+d concept ID	Status
Sevelamer hydrochloride	395871000 Sevelamer (substance) International ID From 08/2005 until 12/2010	History – previous ID
	18308811000001104 - UK extension ID From 12/2010 to date	Current
Sevelamer	18308711000001107 – UK extension ID From 12/2010 to date	Current

In SNOMED UK Drug Extension: 395871000 Sevelamer (substance) – Active 18308811000001104 - Inactive 18308711000001107 - Inactive

The correct international identifier for the ingredient Sevelamer is 395871000 but this cannot be assigned as it was used between 2005 and 2010 and is part of the historical information for the ingredient Sevelamer hydrochloride.

#### **SNOMED International Proposal to Increase Description Length Limit**

We are providing an update to the <u>information previously communicated</u> regarding the proposal from SNOMED International to increase the maximum length of Fully Specified Name and Synonym descriptions,.

SNOMED International have provided <u>further information</u> about the <u>proposal to increase</u> description length limit from 255 to 4096 characters.

NHS England are currently assessing whether this proposed change will impact Fully Specified Names (FSN) created in the SNOMED CT UK Drug Extension. NHS England do not expect that this proposed change will impact Preferred Terms (PT) in the SNOMED CT UK Drug Extension.

This proposal will impact UK users of the **Medicinal Product Hierarchy of the SNOMED International Edition** (both SNOMED CT International Edition and SNOMED CT UK Edition) but dm+d will NOT be affected and we have no plans to adopt these changes.

The planned implementation date for **SNOMED International changes is January 2026** and will come into effect in the **April 2026 UK release**.

Any concerns or queries should be directed to SNOMED International at <a href="mailto:release@snomed.org">release@snomed.org</a>. Please cc <a href="mailto:information.standards@nhs.net">information.standards@nhs.net</a> to enable NHS England to have visibility of UK stakeholder feedback.

## Addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension

The recent work to add the ingredients to Virtual Therapeutic Moieties (VTMs) that needed populating has been completed.

The <u>dm+d Editorial Policy</u> will be updated shortly to reflect the latest policy and will continue to be updated as-and-when any other exclusions are identified. We will provide confirmation when this has been completed.

Please note that VTM Ingredients information will only be available via TRUD and the NHS England Terminology Server from 23 September 2024 and will not be seen in the dm+d browser until further notice is provided.

Additional information about the change is available on the following <u>webpage</u>.

If you have any specific queries relating to the dm+d and SNOMED CT UK Drug Extension changes, please contact <a href="mailto:nhsdigital.ukmeds@nhs.net">nhsdigital.ukmeds@nhs.net</a>

#### Monthly dm+d Supplier Workshop

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries. It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact <a href="mailto:medicinestandards@nhs.net">medicinestandards@nhs.net</a> for more information.

# <u>DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.</u>

Specials/Imports added at request of DHSC to mitigate shortages in the supply chain					
AMP Name	AMP SNOMED Code	Import/Special	dm+d extract date		
Desmopressin 150micrograms/dose nasal spray	38955011000001100	Imported	14/09/2020		
Desmopressin 150micrograms/dose nasal spray	38996011000001101	Special Order	21/09/2020		
Capsaicin 0.025% cream	41539411000001105	Imported	27/03/2023		
Capsaicin 0.075% cream	41540711000001105	Imported	27/03/2023		
Griseofulvin 125mg tablets	42441511000001104	Imported (United States)	27/11/2023		
Griseofulvin 500mg tablets	42441811000001101	Imported (United States)	27/11/2023		
Hydrogen peroxide 3% solution	42510811000001109	Imported	18/12/2023		
Cerium nitrate hexahydrate 22mg/g / Sulfadiazine silver 10mg/g cream	42991011000001101	Imported	01/07/2024		
Sulfadiazine silver 1% cream	42990711000001107	Imported	01/07/2024		
Creon 10000 capsules	43034611000001101	Imported	15/07/2024		
Creon 25000 capsules	43034811000001102	Imported	15/07/2024		
Pancreaze Delayed-Release capsules	43035111000001108	Imported	15/07/2024		
Ipratropium bromide 250micrograms/1ml nebuliser liquid unit dose vials	43093511000001105	Imported	22/07/2024		
Ipratropium bromide 500micrograms/2ml nebuliser liquid unit dose vials	43094411000001109	Imported	22/07/2024		
Methylphenidate 18mg modified-release tablets	43210911000001100	Imported	02/09/2024		
Methylphenidate 27mg modified-release tablets	43211511000001100	Imported	02/09/2024		
Methylphenidate 36mg modified-release tablets	43211911000001107	Imported	02/09/2024		
Methylphenidate 54mg modified-release tablets	43212411000001109	Imported	02/09/2024		
Pangrol 10,000 capsules	43788211000001100	Imported	23/09/2024		
Pangrol 25,000 capsules	43788511000001102	Imported	23/09/2024		
Imiquimod 5% cream 250mg sachets	41526711000001106	Imported	02/12/2024		
Quetiapine 50mg modified-release tablets	44616911000001103	Imported	17/02/2025		
Quetiapine 150mg modified-release tablets	44617411000001108	Imported	17/02/2025		
Quetiapine 200mg modified-release tablets	44617711000001102	Imported	17/02/2025		
Quetiapine 300mg modified-release tablets	44618011000001103	Imported	17/02/2025		
Quetiapine 400mg modified-release tablets	44618311000001100	Imported	17/02/2025		
Fluorouracil 5% cream	44618611000001105	Imported	17/02/2025		
Imiquimod 3.75% cream 250mg sachets	44618911000001104	Imported	17/02/2025		
Sodium fusidate 250mg tablets	44619211000001103	Imported	17/02/2025		
Fusidic acid 250mg/5ml oral suspension	44619511000001100	Special Order	17/02/2025		

### **Invalidations**

None

## **Advance Notice of Invalidations**

The following concept will be invalidated mid-March as it was added erroneously.

Concept to be made Invalid	Replacement concepts	
VMP Amikacin 500mg/2ml solution for injection vials (not to be made invalid)	VMP Amikacin 500mg/2ml solution for injection ampoules	
VMP SNOMED ID 35899911000001109	VMP SNOMED ID 44422511000001103	
VMPP 5 vials (not to be made invalid)	VMPP 5 ampoule	
VMPP SNOMED ID 4500011000001105	VMPP SNOMED ID 44374911000001108	
AMP Amikacin 500mg/2ml solution for injection vials (Kent Pharma (UK) Ltd)	AMP Amikacin 500mg/2ml solution for injection ampoules (Kent Pharma (UK) Ltd)	
<b>AMP SNOMED ID</b> 42788511000001107	AMP SNOMED ID 44375011000001108	
AMPP 5 vials	AMPP 5 ampoule	
<b>AMPP SNOMED ID</b> 42788611000001106	<b>AMPP SNOMED ID</b> 44375111000001109	

dm+d Authoring Team